Literature DB >> 14574441

Constitutive and inducible levels of CYP1A1 and CYP1A2 in rat cerebral cortex and cerebellum.

Michael M Iba1, Amijoy Storch, Anima Ghosal, Susan Bennett, Kenneth R Reuhl, Herbert E Lowndes.   

Abstract

We examined the constitutive and inducible levels of microsomal cytochromes P450 1A1 and 1A2 (CYP1A) in rat cerebral cortex and cerebellum at the level of proteins by western blot analysis, and by catalytic activities via ethoxyresorufin O-deethylase (EROD) and methoxyresorufin O-demethylase (MROD). In the cerebral cortex, cytochrome P450 1A1 (CYP1A1) protein was more abundant than cytochrome P450 1A2 (CYP1A2) protein. Treatment with beta-naphthoflavone (beta-NF) caused a slight decrease in the level of the former but induced the latter 5.8-fold. In the cerebellum, in contrast to the cerebral cortex, CYP1A1 protein was less abundant than CYP1A2 protein in untreated rats, and while beta-NF treatment caused a 3.3-fold induction of CYP1A1 protein, it resulted in a 10-fold decrease in CYP1A2 protein. The CYP1A-preferential activity EROD was 2.3-fold higher in the cerebellum than in the cerebral cortex, and was induced 1.5-fold and 1.9-fold in the cerebellum and cerebral cortex, respectively, by beta-NF treatment. The CYP1A2-preferential activity MROD was 3-fold higher in the cerebellum than in the cerebral cortex, and was repressed 2.2-fold in the cerebellum but induced 3.7-fold in the cerebral cortex following beta-NF treatment. The results show that CYP1A1 and CYP1A2 proteins and catalytic activities are constitutively expressed in brain but are differentially inducible in the rat cerebral cortex and cerebellum.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14574441     DOI: 10.1007/s00204-003-0488-1

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  7 in total

1.  Ahr and Cyp1a2 genotypes both affect susceptibility to motor deficits following gestational and lactational exposure to polychlorinated biphenyls.

Authors:  Breann T Colter; Helen Frances Garber; Sheila M Fleming; Jocelyn Phillips Fowler; Gregory D Harding; Molly Kromme Hooven; Amy Ashworth Howes; Smitha Krishnan Infante; Anna L Lang; Melinda Curran MacDougall; Melinda Stegman; Kelsey Rae Taylor; Christine Perdan Curran
Journal:  Neurotoxicology       Date:  2018-03       Impact factor: 4.294

Review 2.  Blood-brain barrier P450 enzymes and multidrug transporters in drug resistance: a synergistic role in neurological diseases.

Authors:  Chaitali Ghosh; Vikram Puvenna; Jorge Gonzalez-Martinez; Damir Janigro; Nicola Marchi
Journal:  Curr Drug Metab       Date:  2011-10       Impact factor: 3.731

Review 3.  Potential role of cerebral cytochrome P450 in clinical pharmacokinetics: modulation by endogenous compounds.

Authors:  Guillermo Gervasini; Juan Antonio Carrillo; Julio Benitez
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

4.  Cytochrome P450 oxidoreductase participates in nitric oxide consumption by rat brain.

Authors:  Catherine N Hall; Robert G Keynes; John Garthwaite
Journal:  Biochem J       Date:  2009-04-15       Impact factor: 3.857

Review 5.  Pathophysiological implications of neurovascular P450 in brain disorders.

Authors:  Chaitali Ghosh; Mohammed Hossain; Jesal Solanki; Aaron Dadas; Nicola Marchi; Damir Janigro
Journal:  Drug Discov Today       Date:  2016-06-14       Impact factor: 7.851

6.  Cytochrome P450 1A2 Is Incapable of Oxidizing Bilirubin Under Physiological Conditions.

Authors:  Xinyi Li; Dongzhen Yu; Huiqun Jie; Huiqun Zhou; Haibo Ye; Guo Ma; Lili Wan; Chunyan Li; Haibo Shi; Shankai Yin
Journal:  Front Pharmacol       Date:  2019-10-18       Impact factor: 5.810

7.  Developmental exposure to polychlorinated biphenyls interferes with experience-dependent dendritic plasticity and ryanodine receptor expression in weanling rats.

Authors:  Dongren Yang; Kyung Ho Kim; Andrew Phimister; Adam D Bachstetter; Thomas R Ward; Robert W Stackman; Ronald F Mervis; Amy B Wisniewski; Sabra L Klein; Prasada Rao S Kodavanti; Kim A Anderson; Gary Wayman; Isaac N Pessah; Pamela J Lein
Journal:  Environ Health Perspect       Date:  2008-09-12       Impact factor: 9.031

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.